-
Innovation Ranking
NewInnovation Ranking – Rubius Therapeutics Inc
Rubius Therapeutics Inc (Rubius Therapeutics) is a biotechnology company. It focuses on the development of medicines for the treatment of rare diseases, cancer and autoimmune diseases. The company's RCT pipeline products comprise of RTX-240, RTX-321 aAPC, RTX-224, RTX-aAPC, and RTX-T1D. Its products under development are intended for the treatment of human papillomavirus 16-positive cancers, non-small cell lung cancer, type 1 diabetes, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer. The company also offers...
-
Company Insights
Innovation and Patenting activity of Rubius Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Rubius Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Profile
Rubius Therapeutics Inc – Company Profile
Rubius Therapeutics Inc (Rubius Therapeutics) is a biotechnology company. It focuses on the development of medicines for the treatment of rare diseases, cancer and autoimmune diseases. The company's RCT pipeline products comprise of RTX-240, RTX-321 aAPC, RTX-224, RTX-aAPC, and RTX-T1D. Its products under development are intended for the treatment of human papillomavirus 16-positive cancers, non-small cell lung cancer, type 1 diabetes, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer. The company also offers...
Add to Basket -
Product Insights
Net Present Value Model: RTX-321
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model RTX-321 Drug Details RTX-321 is under...
-
Track & Monitor
Innovation in Pharmaceuticals: Genetically modified immunosuppresants
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Genetically modified immunosuppresants segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RTX-321
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RTX-321 Drug Details RTX-321 is under development for the treatment of HPV-16 associated solid...
-
Product Insights
Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cervical Cancer Drugs Market Report Overview Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Its symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding, spotting between periods, and having longer or heavier (menstrual) periods than usual. Key Targets Programmed Cell Death Protein 1, Human Papillomavirus Protein E7, Programmed Cell Death 1 Ligand 1, Human Papillomavirus Protein E6, Cytotoxic T Lymphocyte Protein 4, Vascular Endothelial...
-
Product Insights
Oropharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Oropharyngeal Cancer pipeline drugs market research report provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oropharyngeal Cancer...
-
Product Insights
Head and Neck Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Head and Neck Cancer Pipeline Drugs Market Report Overview Head and Neck Cancer symptoms include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. Treatment includes chemotherapy and radiation therapy. The Head and Neck Cancer pipeline drugs market research report provides an analysis of the Head and Neck Cancer drugs by stage of development, drug target, mechanism of action (MoA), route...